Author

Bethan S. Kilpatrick

BenevolentAI (United Kingdom)

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pathology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Approach:machine learning (classical)· 1 Organism:mouse· 1

Frequent Co-Authors

Aaryaman Sawhney· 1 shared Andrea Taddei· 1 shared Brendan GongoliD· 1 shared Brina Nguyen· 1 shared Cassandra Bui· 1 shared Eduardo Frías-AnayaiD· 1 shared Helios Gallego-GutiérreziD· 1 shared Hemal H. PateliD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPathology

Aaryaman Sawhney

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Integration of artificial intelligence and high-content screening enabled identification of drugs for long-term treatment of cerebral cavernous malformation disease

Eduardo Frías-Anaya, Helios Gallego-Gutiérrez, Cassandra Bui, Janeth O. Birrueta, Jeffrey D. Steinberg, Ingrid R. Niesman, Brendan Gongol, Brina Nguyen, Aaryaman Sawhney, Zaida Mizushima, Nyle Connolly, Bethan S. Kilpatrick, Issam A. Awad, Hemal H. Patel, JoAnn Trejo, , Miguel Alejandro Lopez‐Ramirez

This paper identifies metformin as a potential drug for long-term treatment of cerebral cavernous malformations using AI, high-throughput screening, and animal models.

bioRxiv · Dec 11, 2025 · PreprintPathology